Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 194

Sort by

Sort Order Select

Journal Articles

A First-in-Human Dose Escalation Clinical Trial of Engineered Natural Killer Cell Therapy in Non-Small Cell Lung Cancer Patients Refractory to Immune Check Point Inhibitors

Miguel A Villalona, Lei Tian, Xiaochen Li, Joycelynne Michelle Palmer, Claudia Aceves, Hans Meisen, Catherine Cortez, Tim W Synold, Colt Egelston, Jeffery Vandeusen, Ivone Bruno, Lei Zhang, Eliezer Romeu-Bonilla, Omer Butt, Stephen J. Forman, Michael A Caligiuri, Jianhua Yu

Blood (2024) 144 (Supplement 1): 7206.

https://doi.org/10.1182/blood-2024-202132

Published: 2024

Journal Articles

Human ILC1s Target Leukemia Stem Cells and Control Development of AML

Zhenlong Li, Hejun Tang, Victoria Chen, Rui Ma, Jianying Zhang, Guido Marcucci, Jianhua Yu, Michael A Caligiuri

Blood (2023) 142 (Supplement 1): 886.

https://doi.org/10.1182/blood-2023-190767

Published: 2023

Journal Articles

The NK Cell Receptor NKp46 Acts As an Essential Regulator of ILC1 Proliferation, Effector Function and Anti-AML Activity

Rui Ma, Zhenlong Li, Hejun Tang, Lei Tian, Zahir Shah, Tasha Barr, Amy Peng, Jianying Zhang, Srividya Swaminathan, Michael A Caligiuri, Jianhua Yu

Blood (2023) 142 (Supplement 1): 3925.

https://doi.org/10.1182/blood-2023-191070

Published: 2023

Journal Articles

Acquired microRNA-142 Deficit Drives Escape Mechanisms of Anti-Leukemic Surveillance during Blast Crisis Transformation of Chronic Myeloid Leukemia (CML)

Blood (2023) 142 (Supplement 1): 3152.

https://doi.org/10.1182/blood-2023-182587

Published: 2023

Journal Articles

Targeting EBV Encoded Viral Kinases with GCV, AZT, Rituximab and Dexamethasone (GARD) Results in Durable Responses in Patients with CNS Lymphoproliferative Disease

Haley L. Klimaszewski, Christoph Weigel, Selamawit Addissie, Sarah Schlotter, Tounkara Fode, James P. Dugan, Bradley M. Haverkos, Lynda Villagomez, Mark Lustberg, Pierluigi Porcu, Timothy Voorhees, Michael A Caligiuri, Christopher C. Oakes, Ginny Bumgardner, Robert Baiocchi

Blood (2023) 142 (Supplement 1): 4476.

https://doi.org/10.1182/blood-2023-189618

Published: 2023

Journal Articles

Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia

Caroline Duault, Anil Kumar, Adeleh Taghi Khani, Sung June Lee, Lu Yang, Min Huang, Christian Hurtz, Bryan Manning, Lucy Ghoda, Tinisha McDonald, Norman J. Lacayo, Kathleen M. Sakamoto, Martin Carroll, Sarah K. Tasian, Guido Marcucci, Jianhua Yu, Michael A. Caligiuri, Holden T. Maecker, Srividya Swaminathan

Blood (2021) 138 (16): 1465–1480.

https://doi.org/10.1182/blood.2020009871

Published: 2021

Includes: Supplemental data

Journal Articles

Role of Mir-29b in T-Cell Development and in Cutaneous T-Cell Lymphoma Pathogenesis

Anthony Mansour, MD, David Clever, Colleen Isabelle, Amy E Boles, BS, Kathleen McConnell, Zhiyao Li, Logan A Chrislip, Michael A. Caligiuri, MD, Anjali Mishra, PhD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-142145

Published: 2020

Journal Articles

Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia

Caroline Duault, PharmD, PhD, Anil Kumar, PhD, Adeleh Taghi Khani, PhD, Sung June Lee, BA, Lu Yang, PhD, Min Huang, PhD, Christian Hurtz, PhD, Bryan Manning, BS, Lucy Ghoda, PhD, Tinisha McDonald, BS, Norman J. Lacayo, MD, Kathleen M. Sakamoto, MD PhD, Martin P. Carroll, MD, Guido Marcucci, MD, Jianhua Yu, PhD, Michael A. Caligiuri, MD, Holden T. Maecker, PhD, Srividya Swaminathan, PhD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-140044

Published: 2020

Journal Articles

FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia

Le Xuan Truong Nguyen, PhD, Bin Zhang, PhD, Dinh Hoa Hoang, BS, Dandan Zhao, MD, Sergio Branciamore, Davide Maestrini, PhD, Yu-Lin SU, PhD, Sonia Rodriguez, PhD, Flavia Pichiorri, PhD, Steven Rosen, MD, Michael A. Caligiuri, MD, Stephen J. Forman, MD, Ling Li, PhD, Marcin Kortylewski, PhD, Russell Rockne, PhD, Ya-Huei Kuo, PhD, Nadia Carlesso, MD, Guido Marcucci, MD

Blood (2019) 134 (Supplement_1): 2722.

https://doi.org/10.1182/blood-2019-131871

Published: 2019

Journal Articles

BZLF1-DEC205 Fusion Protein Enhances EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease

Elshafa Hassan Ahmed, DVM, Eric Brooks, Shelby Sloan, BS, Sarah Schlotter, Frankie Jeney, Charlene Mao, Polina Shindiapina, MD PhD, Salma Shire, Claire Hale, Manjusri Das, Alexander Prouty, Michael A. Caligiuri, MD, Robert A Baiocchi, MD PhD

Blood (2018) 132 (Supplement 1): 342.

https://doi.org/10.1182/blood-2018-99-117837

Published: 2018

Journal Articles

Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function

Blood (2018) 132 (17): 1792–1804.

https://doi.org/10.1182/blood-2018-03-838474

Published: 2018

Includes: Supplemental data

Journal Articles

Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma

Rebecca Kohnken, Jing Wen, Bethany Mundy-Bosse, Kathleen McConnell, Ashleigh Keiter, Leah Grinshpun, Alex Hartlage, Max Yano, Betina McNeil, Nitin Chakravarti, Basem William, James E. Bradner, Michael A. Caligiuri, Pierluigi Porcu, Anjali Mishra

Blood (2018) 131 (7): 771–781.

https://doi.org/10.1182/blood-2017-09-805663

Published: 2018

Includes: Supplemental data

Journal Articles

Enhanced Spontaneous Anti-Tumor Cytotoxicity of Natural Killer Cells in Cutaneous T-Cell Lymphoma Patients

Bethany L Mundy-Bosse, PhD, Nathan Denlinger, MS, DO, Susan Huang, MD, Li Chen, Hsiaoyin Mao, David Kline, Eric McLaughlin, Youssef Youssef, Karen Young, Gerard Lozanski, MD, Aharon G. Freud, MD PhD, Pierluigi Porcu, MD, Basem M. William, MD, Michael A. Caligiuri, MD, Anjali Mishra, PhD

Blood (2017) 130 (Supplement 1): 2753.

https://doi.org/10.1182/blood.V130.Suppl_1.2753.2753

Published: 2017

Journal Articles

Malignant NK Cells from EBV(+) Human Extranodal NK/T Cell Lymphoma Exhibit Features of a Distinct NK Cell Developmental Subset Found in Mucosal Associated Lymphoid Tissue

Anjali Mishra, PhD, Bethany L Mundy-Bosse, PhD, Karen A Young, Christoph Weigel, PhD, Emily Smith, Ahmed Elshafa, Youssef Youssef, Kathleen McConnell, Christoph Plass, PhD, Jonathan E Brammer, MD, Robert A Baiocchi, MD PhD, Michael A. Caligiuri, MD, Pierluigi Porcu, MD, Aharon G. Freud, MD PhD, Christopher C. Oakes, PhD

Blood (2017) 130 (Supplement 1): 1451.

https://doi.org/10.1182/blood.V130.Suppl_1.1451.1451

Published: 2017

Journal Articles

Targeting BRD4 Disables IL-15 Oncogenic Signaling in Cutaneous T-Cell Lymphoma Via Down Regulation of IL-15 Receptor Complex

Rebecca Kohnken, Jing Wen, Max Yano, Alex Hartlage, BS, Leah Grinshpun, Michael A. Caligiuri, MD, Pierluigi Porcu, MD, Anjali Mishra, PhD

Blood (2016) 128 (22): 1097.

https://doi.org/10.1182/blood.V128.22.1097.1097

Published: 2016

Journal Articles

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3238.

https://doi.org/10.1182/blood.V128.22.3238.3238

Published: 2016

Journal Articles

A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485

Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ramiro Garzon, MD, Alison R. Walker, MD MPH, Steven M. Devine, MD, Katherine J. Walsh, MD, Sumithira Vasu, MBBS, Susan P. Whitman, PhD, Guido Marcucci, MD, Nyla A. Heerema, PhD, Michael A. Caligiuri, MD, Clara D. Bloomfield, MD, John C. Byrd, MD, Richard Piekarz, PhD MD, Michael R. Grever, MD, William Blum, MD

Blood (2016) 128 (22): 900.

https://doi.org/10.1182/blood.V128.22.900.900

Published: 2016

Journal Articles

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

Justine Yu, B.S., Giovannino Silvestri, PhD, Lorenzo Stramucci, PhD, Masashi Sanada, MD PhD, Tomoyuki Yamaguchi, PhD, Yang Du, PhD, Jukka Westermarck, MD PhD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, Dragana Milojkovic, MD, Jane F. Apperley, MD, Denis-Claude Roy, MD, Guido Marcucci, MD, Bruno Calabretta, MD PhD, Maria R. Baer, MD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD

Blood (2016) 128 (22): 2909.

https://doi.org/10.1182/blood.V128.22.2909.2909

Published: 2016

Journal Articles

EGFL7 Antagonizes NOTCH Signaling, Stimulates Blast Proliferation and Confers Poor Prognosis in Cytogenetically-Normal Acute Myeloid Leukemia (CN-AML)

Changxian Shen, Dimitrios Papaioannou, MD, Betina Mcneil, Deedra Nicolet, Malith Karunasiri, Matthew Burke, Zitzer Nina, Gregory K. Behbehani, MD PhD, Hatice G Ozer, PhD, Selen Yilmaz, Guido Marcucci, MD, Michael A. Caligiuri, MD, Clara D. Bloomfield, MD, Ramiro Garzon, MD, Adrienne Dorrance, PhD

Blood (2016) 128 (22): 2689.

https://doi.org/10.1182/blood.V128.22.2689.2689

Published: 2016

Journal Articles

Decitabine enhances anti-CD33 monoclonal antibody BI 836858–mediated natural killer ADCC against AML blasts

Blood (2016) 127 (23): 2879–2889.

https://doi.org/10.1182/blood-2015-11-680546

Published: 2016

Includes: Supplemental data

NARROW

A First-in-Human Dose Escalation Clinical Trial of Engineered Natural Killer Cell Therapy in Non-Small Cell Lung Cancer Patients Refractory to Immune Check Point Inhibitors

Human ILC1s Target Leukemia Stem Cells and Control Development of AML

The NK Cell Receptor NKp46 Acts As an Essential Regulator of ILC1 Proliferation, Effector Function and Anti-AML Activity

Acquired microRNA-142 Deficit Drives Escape Mechanisms of Anti-Leukemic Surveillance during Blast Crisis Transformation of Chronic Myeloid Leukemia (CML)

Targeting EBV Encoded Viral Kinases with GCV, AZT, Rituximab and Dexamethasone (GARD) Results in Durable Responses in Patients with CNS Lymphoproliferative Disease

Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia

Role of Mir-29b in T-Cell Development and in Cutaneous T-Cell Lymphoma Pathogenesis

Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia

FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia

BZLF1-DEC205 Fusion Protein Enhances EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease

Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function

Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma

Enhanced Spontaneous Anti-Tumor Cytotoxicity of Natural Killer Cells in Cutaneous T-Cell Lymphoma Patients

Malignant NK Cells from EBV(+) Human Extranodal NK/T Cell Lymphoma Exhibit Features of a Distinct NK Cell Developmental Subset Found in Mucosal Associated Lymphoid Tissue

Targeting BRD4 Disables IL-15 Oncogenic Signaling in Cutaneous T-Cell Lymphoma Via Down Regulation of IL-15 Receptor Complex

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

EGFL7 Antagonizes NOTCH Signaling, Stimulates Blast Proliferation and Confers Poor Prognosis in Cytogenetically-Normal Acute Myeloid Leukemia (CN-AML)

Decitabine enhances anti-CD33 monoclonal antibody BI 836858–mediated natural killer ADCC against AML blasts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only